Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Stockholders Equity (Deficit)

v3.20.2
Condensed Consolidated Statements of Stockholders Equity (Deficit) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Noncontrolling Interest [Member]
Series B Preferred Stock [Member]
Total
Balance at Dec. 31, 2018 $ 15 $ 230,754 $ (219,461) $ (2,909) $ 5,760 $ 14,159
Balance (in shares) at Dec. 31, 2018 15,482,083       9,161  
Stock-based compensation $ 0 64 0 0 $ 0 64
Series A Preferred Stock Dividends 0 0 (61) 0 0 (61)
Issuance of SYN Biomics Stock $ 0 (36) 0 53 $ 0 17
Conversion of Series B Preferred Stock to Common (in shares) 900,869       (1,036)  
Conversion of Series B Preferred Stock to Common $ 1 1,035 (398) 0 $ (638) 0
Net loss 0 0 (3,512) 0 0 (3,512)
Non-controlling interest 0 0 0 (16) 0 (16)
Balance at Mar. 31, 2019 $ 16 231,817 (223,432) (2,872) $ 5,122 10,651
Balance (in shares) at Mar. 31, 2019 16,382,952       8,125  
Balance at Dec. 31, 2018 $ 15 230,754 (219,461) (2,909) $ 5,760 14,159
Balance (in shares) at Dec. 31, 2018 15,482,083       9,161  
Net loss           (12,163)
Non-controlling interest           (73)
Balance at Sep. 30, 2019 $ 17 232,485 (232,394) (2,854) $ 4,822 2,089
Balance (in shares) at Sep. 30, 2019 16,806,430       7,638  
Balance at Mar. 31, 2019 $ 16 231,817 (223,432) (2,872) $ 5,122 10,651
Balance (in shares) at Mar. 31, 2019 16,382,952       8,125  
Stock-based compensation $ 0 91 0 0 $ 0 91
Series A Preferred Stock Dividends 0 0 (61) 0 0 (61)
Issuance of SYN Biomics Stock $ 0 0 0 45 $ 0 45
Conversion of Series B Preferred Stock to Common (in shares) 262,608       (302)  
Conversion of Series B Preferred Stock to Common $ 1 303 (117) 0 $ (187) 0
Net loss 0 0 (3,531) 0 0 (3,531)
Non-controlling interest 0 0 0 (27) 0 (27)
Balance at Jun. 30, 2019 $ 17 232,211 (227,141) (2,854) $ 4,935 7,168
Balance (in shares) at Jun. 30, 2019 16,645,560       7,823  
Stock-based compensation $ 0 91 0 0 $ 0 91
Series A Preferred Stock Dividends 0 0 (63) 0 0 (63)
Issuance of SYN Biomics Stock $ 0 0 0 43 $ 0 43
Conversion of Series B Preferred Stock to Common (in shares) 160,870       (185)  
Conversion of Series B Preferred Stock to Common $ 0 183 (70) 0 $ (113) 0
Net loss 0 0 (5,120) 0 0 (5,120)
Non-controlling interest 0 0 0 (30) 0 (30)
Balance at Sep. 30, 2019 $ 17 232,485 (232,394) (2,854) $ 4,822 2,089
Balance (in shares) at Sep. 30, 2019 16,806,430       7,638  
Balance at Dec. 31, 2019 $ 17 232,580 (235,537) (2,878) $ 4,761 (1,057)
Balance (in shares) at Dec. 31, 2019 16,806,430       7,638  
Stock-based compensation $ 0 83 0 0 $ 0 83
Series A Preferred Stock Dividends 0 0 (62) 0 0 (62)
Issuance of SYN Biomics Stock $ 0 0 0 26 $ 0 26
Conversion of Series B Preferred Stock to Common (in shares) 933,045       (1,073)  
Conversion of Series B Preferred Stock to Common $ 1 1,072 (404) 0 $ (669) 0
Net loss 0 0 (2,964) 0 0 (2,964)
Non-controlling interest 0 0 0 (26) 0 (26)
Balance at Mar. 31, 2020 $ 18 233,735 (238,967) (2,878) $ 4,092 (4,000)
Balance (in shares) at Mar. 31, 2020 17,739,475       6,565  
Balance at Dec. 31, 2019 $ 17 232,580 (235,537) (2,878) $ 4,761 (1,057)
Balance (in shares) at Dec. 31, 2019 16,806,430       7,638  
Net loss           (7,934)
Non-controlling interest           (50)
Balance at Sep. 30, 2020 $ 20 236,320 (244,975) (2,750) $ 2,584 (8,801)
Balance (in shares) at Sep. 30, 2020 19,842,955       4,146  
Balance at Mar. 31, 2020 $ 18 233,735 (238,967) (2,878) $ 4,092 (4,000)
Balance (in shares) at Mar. 31, 2020 17,739,475       6,565  
Stock-based compensation $ 0 86 0 0 $ 0 86
Series A Preferred Stock Dividends 0 0 (63) 0 0 (63)
Issuance of SYN Biomics Stock $ 0 0 0 10 $ 0 10
Conversion of Series B Preferred Stock to Common (in shares) 904,349       (1,040)  
Conversion of Series B Preferred Stock to Common $ 1 1,039 (392) 0 $ (648) 0
Net loss 0 0 (2,867) 0 0 (2,867)
Non-controlling interest 0 0 0 (16) 0 (16)
Balance at Jun. 30, 2020 $ 19 234,860 (242,289) (2,884) $ 3,444 (6,850)
Balance (in shares) at Jun. 30, 2020 18,643,824       5,525  
Stock-based compensation $ 0 82 0 0 $ 0 82
Series A Preferred Stock Dividends 0 0 (64) 0 0 (64)
Issuance of SYN Biomics Stock $ 0 0 0 142 $ 0 142
Conversion of Series B Preferred Stock to Common (in shares) 1,199,131       (1,379)  
Conversion of Series B Preferred Stock to Common $ 1 1,378 (519) 0 $ (860) 0
Net loss 0 0 (2,103) 0 0 (2,103)
Non-controlling interest 0 0 0 (8) 0 (8)
Balance at Sep. 30, 2020 $ 20 $ 236,320 $ (244,975) $ (2,750) $ 2,584 $ (8,801)
Balance (in shares) at Sep. 30, 2020 19,842,955       4,146